Summarized by Masters of Longevity from Longevity Technology.
A preview of a scientific conference presentation sharing interim clinical safety and tolerability data for an investigational liver disease cell therapy, with context on the research program.
Key Takeaways
- Interim data from the Phase I/II EMERALD study of RTX001 will be presented as a late-breaking AASLD abstract.
- EMERALD is a multi-center, single-arm, first-in-human, open-label study in patients recovered from recent hepatic decompensation.
- Resolution Therapeutics is a University of Edinburgh spinout with lead product RTX001 reported to have preclinical anti-fibrotic and anti-inflammatory activity.
